The Effect Of Model-Based Dıgıtal Game On Metabolıc Control, Self-Effıcıency And Qualıty Of Lıfe In Chıldren Wıth Type 1 Dıabetes
Condition(s) studied
Investigational drug(s) / intervention(s)
Dijital Game and Health Education: After the children in the experimental group are informed about the digital game designed according to The The Information-Motivation-Behavioral Skills Model (IMB) in diabetes management, active participation of the children in the digital game will be ensured for 9 weeks; and participation status will be followed in the background of the game. At the end of 9 weeks, children will be asked to complete all stages of the game. Children who do not complete the game will be contacted once a week in line with their background follow-up and reminders will be made.
Study summary
This study was planned to determine the effect of model-based digital game on metabolic control, self-efficacy and quality of life in children with T1DM.
Eligibility
Primary outcome measure(s)
- Quality of Life Scale for Children with Type 1 Diabetes (PedsQL 3.0) — 30 minutes
The scale was developed by Varni et al in 2003. It consists of five sub-dimensions: diabetes symptoms, treatment barriers, adherence to treatment, anxiety, and communication. The scale was prepared in a five-point Likert type, and the child form of the scale was designed for 5-7 age groups, 8-12 age groups and 13-18 age groups. A high total score from the scale indicates a high health-related quality of life. The internal consistency coefficient of the original form of the scale was 0.71(Varni et al,2003). The Turkish validity and reliability study of the 8-12 age form of the scale was performed by Ayar(2012), and the Turkish validity and reliability study of the 13-18 age form was performed by Çövener Özçelik et al(2015). In the study, the Cronbach's alpha values of the scales were 0.83 for 8-12 years old, 0.90 for 13-18 years old. In the studies of Ayar and Öztürk(2016); The internal consistency coefficient of the quality of life scale in children with diabetes was found to be 0.80.
Trial sites (2)
| Facility | City | Region | Status |
|---|---|---|---|
| Bolu Abant İzzet Baysal Üniversitesi | Bolu | Turkey (Türkiye) | Recruiting |
| Zonguldak Bülent Ecevit Üniversitesi | Zonguldak | Turkey (Türkiye) | Recruiting |
More Abant Izzet Baysal University trials in Turkey
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05923632 on ClinicalTrials.gov ↗ ← All trials in Turkey